Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Biomarkers of ECM Remodeling Reflect Pharmacodynamic Effects of IMU-856
March 27, 2026
Biomarkers of Extracellular Matrix Remodeling Reflect Pharmacodynamic Effects on IMU-856, an Oral Epigenetic Modulator of Barrier Regeneration
Introduction
Celiac disease (CeD) is characterized by intestinal inflammation and epithelial damage upon exposure to immunogenic gluten peptide, directly disrupting tissue architecture and by extension the extracellular matrix (ECM). The intestinal tissue is rich in ECM proteins such as collagens, which, during inflammation, undergo enzymatic remodeling due to increased proteolytic activity.
IMU-856 is an orally available and systematically acting small-molecule modulator of sirtuin 6 (SIRT6), a histone/non-histone protein deacetylase and transcriptional regulator that aims to restore intestinal barrier function and regenerate bowel epithelium.
This study aimed to investigate biomarkers of ECM remodeling as potential indicators of disease activity and pharmacodynamic response to IMU-856 in patients with CeD.
Poster
Conclusion
Biomarkers of ECM remodeling reflect histological inflammation and mucosal architecture parameters, offering a direct insight into intestinal barrier integrity. These biomarkers potentially reflect treatment-induced improvement in intestinal tissue remodeling upon treatment with IMU-856.
